Royal Bank of Canada
SYRS

Royal Bank of Canada’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Royal Bank of Canada’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,100
Closed -$2K – 7365
2024
Q3 		$2K Sell
1,100
-2,321
-68% -$8.34K ﹤0.01% 6674
2024
Q2 		$18K Buy
3,421
+2,103
+160% +$11.1K ﹤0.01% 6124
2024
Q1 		$7K Sell
1,318
-1,682
-56% -$11.6K ﹤0.01% 6361
2023
Q4 		$23K Buy
3,000
+2,058
+218% +$7.05K ﹤0.01% 6265
2023
Q3 		$4K Sell
942
-559
-37% -$2.09K ﹤0.01% 6685
2023
Q2 		$5K Buy
1,501
+1,249
+496% +$4.01K ﹤0.01% 6695
2023
Q1 		$1K Buy
252
+245
+3,500% +$950 ﹤0.01% 6955
2022
Q4 		$0 Sell
7
-29
-81% -$126 ﹤0.01% 7840
2022
Q3 		$0 Sell
36
-17
-32% -$138 ﹤0.01% 7974
2022
Q2 		$0 Sell
53
-301
-85% -$2.82K ﹤0.01% 7806
2022
Q1 		$4K Sell
354
-896
-72% -$16K ﹤0.01% 7347
2021
Q4 		$40K Buy
1,250
+762
+156% +$30.9K ﹤0.01% 6501
2021
Q3 		$22K Buy
488
+94
+24% +$4.59K ﹤0.01% 6665
2021
Q2 		$21K Buy
394
+199
+102% +$11.8K ﹤0.01% 6545
2021
Q1 		$15K Buy
195
+69
+55% +$7.17K ﹤0.01% 6613
2020
Q4 		$14K Sell
126
-1,000
-89% -$91.3K ﹤0.01% 6240
2020
Q3 		$100K Buy
1,126
+519
+86% +$59K ﹤0.01% 4980
2020
Q2 		$65K Buy
607
+589
+3,272% +$52.9K ﹤0.01% 5107
2020
Q1 		$1K Sell
18
-134
-88% -$9.09K ﹤0.01% 6511
2019
Q4 		$11K Buy
+152
New +$9.22K ﹤0.01% 6119
2019
Q1 		– Sell
-3
Closed – – 7173
2018
Q4 		$0 Sell
3
-53
-95% -$4.03K ﹤0.01% 7194
2018
Q3 		$6K Buy
56
+41
+273% +$4.76K ﹤0.01% 6213
2018
Q2 		$2K Buy
+15
New +$1.86K ﹤0.01% 6279
2018
Q1 		– Sell
-3
Closed – – 6878
2017
Q4 		$0 Sell
3
-104
-97% -$14K ﹤0.01% 6965
2017
Q3 		$16K Buy
107
+105
+5,250% +$19.7K ﹤0.01% 6078
2017
Q2 		$0 Sell
2
-58
-97% -$9.11K ﹤0.01% 6816
2017
Q1 		$10K Buy
60
+36
+150% +$4.39K ﹤0.01% 5985
2016
Q4 		$3K Buy
24
+14
+140% +$1.96K ﹤0.01% 6425
2016
Q3 		$1K Buy
+10
New +$1.27K ﹤0.01% 6318

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Royal Bank of Canada's SYRS Position: Q4 2024 in Review

Royal Bank of Canada sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2024, closing a stake of 1,100 shares — an estimated $2K sold.

Royal Bank of Canada first reported a position in SYRS in Q3 2016 and held it in 29 quarters. The position peaked at $100K in Q3 2020. 44 funds tracked by Wall St. Rank hold SYRS as of Q4 2024.

  • Royal Bank of Canada reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 1,100 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $2K.
  • Royal Bank of Canada first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2016 and held it in 29 quarters.
  • Royal Bank of Canada's Syros Pharmaceuticals, Inc. Common Stock position peaked at $100K in Q3 2020.
  • 44 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Royal Bank of Canada's 13F filing for Q4 2024, filed 14 Feb 2025.